RXST - RxSight, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $10.25 DETAILS

Stock News

RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum

ALISO VIEJO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., today announced plans to participate in the upcoming Stifel 2026 Virtual Ophthalmology Forum. Management is scheduled to participate in a fireside chat on Tuesday, May 26, 2026, at 10:00 a.m. Pacific Time. A live and archived webcast of the presentation will be available on the company's investor relations website at https://investors.rxsight.com/.

May 19, 2026 12:10 PM • globenewswire.com

RxSight, Inc. (RXST) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 13, 2026 03:20 PM • seekingalpha.com

RxSight, Inc. (RXST) Q1 2026 Earnings Call Transcript

May 09, 2026 12:31 PM • seekingalpha.com

RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates

RxSight, Inc. (RXST) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.03 per share a year ago.

May 06, 2026 03:31 PM • zacks.com

RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook

ALISO VIEJO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended March 31, 2026.

May 06, 2026 12:05 PM • globenewswire.com

RxSight, Inc. to Present at the Bank of America Healthcare Conference

ALISO VIEJO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., today announced plans to participate in the upcoming Bank of America Healthcare Conference. Management is scheduled to participate in a fireside chat on Wednesday, May 13, 2026, at 3:00 p.m. Pacific Time. A live and archived webcast of the presentation will be available on the company's investor relations website at https://investors.rxsight.com/.

Apr 29, 2026 12:10 PM • globenewswire.com

RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6

ALISO VIEJO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the first quarter after the market close on Wednesday, May 6, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Apr 22, 2026 12:10 PM • globenewswire.com

RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026

WASHINGTON, April 08, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced, in advance of the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, that over 300,000 Light Adjustable Lens® (LAL®) implants have been performed since launch, marking a significant milestone in the company's pursuit to make customized vision correction widely available to patients.

Apr 08, 2026 12:05 PM • globenewswire.com

RxSight (NASDAQ:RXST) Trading Down 3.7% – Time to Sell?

Shares of RxSight, Inc. (NASDAQ: RXST - Get Free Report) fell 3.7% on Tuesday. The company traded as low as $6.75 and last traded at $6.76. 430,271 shares were traded during trading, a decline of 45% from the average session volume of 784,773 shares. The stock had previously closed at $7.02. Analyst Ratings Changes A

Apr 07, 2026 10:39 PM • defenseworld.net

RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference

ALISO VIEJO, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., today announced plans to participate in the upcoming 25th Annual Needham Virtual Healthcare Conference. Management is scheduled to participate in a fireside chat on Thursday, April 16, 2026, at 8:00 a.m. Pacific Time. A live and archived webcast of the presentation will be available on the company's investor relations website at https://investors.rxsight.com/.

Apr 02, 2026 12:10 PM • globenewswire.com

RxSight, Inc. (NASDAQ:RXST) Given Consensus Rating of “Reduce” by Analysts

RxSight, Inc. (NASDAQ: RXST - Get Free Report) has received a consensus recommendation of "Reduce" from the fifteen analysts that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have given a buy rating to the company. The average

Mar 16, 2026 10:24 PM • defenseworld.net

Short Interest in RxSight, Inc. (NASDAQ:RXST) Expands By 29.3%

RxSight, Inc. (NASDAQ: RXST - Get Free Report) was the target of a large increase in short interest in February. As of February 13th, there was short interest totaling 5,358,739 shares, an increase of 29.3% from the January 29th total of 4,144,635 shares. Approximately 14.4% of the company's stock are sold short. Based on an average

Mar 02, 2026 08:03 PM • defenseworld.net

RxSight, Inc. (RXST) Q4 2025 Earnings Call Transcript

Feb 25, 2026 06:17 PM • seekingalpha.com

RxSight, Inc. (RXST) Reports Q4 Loss, Beats Revenue Estimates

RxSight, Inc. (RXST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.03 per share a year ago.

Feb 25, 2026 03:25 PM • zacks.com

Earnings Preview: RxSight, Inc. (RXST) Q4 Earnings Expected to Decline

RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Feb 18, 2026 06:00 AM • zacks.com

RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

ALISO VIEJO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the fourth quarter and full year 2025 after the market close on Wednesday, February 25, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Feb 11, 2026 11:10 AM • globenewswire.com

Head to Head Analysis: RxSight (NASDAQ:RXST) vs. Edap Tms (NASDAQ:EDAP)

Edap Tms (NASDAQ: EDAP - Get Free Report) and RxSight (NASDAQ: RXST - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings. Profitability This table compares Edap Tms and RxSight's

Feb 08, 2026 08:56 PM • defenseworld.net

Baillie Gifford & Co. Raises Stock Holdings in RxSight, Inc. $RXST

Baillie Gifford and Co. boosted its stake in shares of RxSight, Inc. (NASDAQ: RXST) by 46.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 686,316 shares of the company's stock after purchasing an additional 217,371

Jan 25, 2026 10:36 PM • defenseworld.net

RxSight, Inc. (NASDAQ:RXST) Given Consensus Rating of “Reduce” by Analysts

RxSight, Inc. (NASDAQ: RXST - Get Free Report) has received a consensus rating of "Reduce" from the thirteen ratings firms that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and one has given a buy recommendation to the company. The

Jan 25, 2026 09:22 PM • defenseworld.net

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Jan 22, 2026 05:00 AM • prnewswire.com (Hide legal announcements)